Increased IDO has been reported in a broad range of tumor types and can predict poor survival.


Indoximod is an orally administered, small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophanand high kynurenine that result from IDO activity. Indoximod has immunostimulatory effects involving 3 main cell types: CD8+ T cells, T regulatory cells, and dendritic cells:

  • • Reverses the effects of low tryptophan by increasing proliferation of effector T cells
  • • Directly reprograms T regulatory cells into helper T cells
  • • Downregulates IDO expression in dendritic cells


Clinical data suggest indoximod combinations may enhance multiple therapeutic modalities. Indoximod has the potential to improve patient outcomes across both hematologic cancer and solid tumor indications.

Posters and Publications


1. Wainwright DA, et al. Clin Cancer Res. 2012;18(22):6110-6121.
2. Munn DH, et al. J Clin Invest. 2004;114(2):280-290.
3. Speeckaert R, et al. Eur J Cancer. 2012;48(13):2004-2011.
4. Hamid O, et al. J Transl Med. 2011;9:204.
5. Brandacher G, et al. Clin Cancer Res. 2006;12(4):1144-1151.
6. Ferdinande L, et al. Br J Cancer. 2012;106(1):141-147.
7. Chamuleau ME, et al. Haematologica. 2008;93(12):1894-1898.
8. Corm S, et al. Leuk Res. 2009;33(3):490-494.
9. Watkins SK, et al. J Clin Invest. 2011;121(4):1361-1372.
10. Mansfield AS, et al. BMC Cancer. 2009;9:231.
11. Okamoto A, et al. Clin Cancer Res. 2005;11(16):6030-6039.
12. Ino K, et al. Br J Cancer. 2006;95(11):1555-1561.
13. Inaba T, et al. Gynecol Oncol. 2010;117(3):423-428.